Table 1 Clinical characteristics of patients in the training and validation cohorts.

From: Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy

Variables

Value

Training cohort (n = 139)

Validation cohort (n = 225)

LDH ≥ 185

LDH < 185

p-value*

LDH ≥ 185

LDH < 185

p-value*

Age (years)

<60

15

39

0.226

33

45

0.636

≥60

22

63

 

63

84

 

Sex

Male

19

64

0.805

49

97

0.937

Female

18

38

 

29

50

 

Stage

III

8

40

0.054

12

32

0.251

IV

29

62

 

66

115

 

CA 19-9 (IU/ml)

≥1000

20

48

0.335

40

69

0.138

<1000

17

54

 

38

78

 

Location

Head

19

43

0.466

23

55

0.535

Body/tail

18

59

 

58

89

 

PLR

≥154

15

40

0.888

25

49

0.846

<154

22

62

 

53

98

 

NLR

≥3.42

19

27

0.006

38

56

0.124

<3.42

18

75

 

40

91

 

LMR

≥3.19

16

51

0.481

35

81

0.144

<3.19

21

51

 

43

66

 

KPS

≥90

8

44

0.028

51

86

0.314

<90

29

58

 

51

61

 

Metastasis

Intrahepatic

26

48

0.163

58

97

0.01

Extrahepatic

3

14

 

3

23

 

Location of intrahepatic metastasis

Left Lobe

0

0

0.323

1

5

0.249

Right Lobe

1

5

 

5

12

 

Left&Right Lobe

25

43

 

51

81

 

Albumin (g/L)

≥38.6

18

66

0.087

58

106

0.718

<38.6

19

36

 

20

41

 
  1. *Pearson χ2test.
  2. LDH, lactate dehydrogenase; KPS, Karnofsky performance status.